文献速递瓣膜外科

经颈动脉与经锁骨下入路TAVR结局比较

Comparative Outcomes of Transcarotid and Transsubclavian Transcatheter Aortic Valve Replacement.
PubMed 文献 · Ann Thorac Surg · 2019-07-04

本研究回顾性比较了单中心2016年1月至2018年10月间经颈动脉(33例)与经锁骨下(38例)入路行TAVR的安全性和有效性。两组瓣膜置入成功率、住院及30天死亡率、卒中及血管并发症无显著差异;经颈动脉组手术时间更短,透视空气比释动能更低。

要点

  • 经颈动脉与经锁骨下TAVR安全性和有效性相似。
  • 经颈动脉组手术时间更短(110±32 vs 134±45分钟)。
  • 经颈动脉组透视空气比释动能更低,但剂量面积乘积无差异。

核心结论

  • 经颈动脉与经锁骨下入路TAVR具有相似的安全性和有效性结局。
  • 经颈动脉入路手术时间更短,透视时间及辐射暴露有降低趋势。

研究设计与样本

  • 单中心回顾性分析,纳入2016年1月至2018年10月间经颈动脉或经锁骨下入路TAVR患者。
  • 经颈动脉组33例,经锁骨下组38例;结局按VARC定义报告。

临床怎么用

  • 对于无法经股动脉入路的严重主动脉瓣狭窄患者,经颈动脉和经锁骨下入路均可作为TAVR的替代选择。
  • 经颈动脉入路可能缩短手术时间并降低透视辐射剂量,但需结合患者解剖条件选择。

局限性

  • 回顾性单中心研究,样本量较小(共71例)。
  • 经颈动脉组年龄显著大于经锁骨下组,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Previous reports described successful use of transcarotid and transsubclavian approaches for the performance of transcatheter aortic valve replacement (TAVR) in patients with severe aortic stenosis who cannot be treated with transfemoral access. The purpose of the present study was to compare these two alternative approaches with respect to safety, efficacy, and procedural efficiency. METHODS: A retrospective analysis of all TAVR procedures performed through either a transcarotid or a transsubclavian approach at a single tertiary care medical center between January 2016 and October 2018 was performed. Outcomes are reported in accordance with the Valve Academic Research Consortium definitions. RESULTS: During the study period, 33 patients had transcarotid TAVR and 38 patients had transsubclavian TAVR. Transcarotid patients were older (mean age, 82.9 ± 7.2 vs 78.1 ± 8.2 years; P = .012), but otherwise the two groups were not significantly different with respect to preoperative characteristics. Valve deployment was similar between the groups (100% vs 97%; P = .348). Procedure time was shorter with the transcarotid approach (110 ± 32 vs 134 ± 45 minutes; P = .014). There was a lower mean fluoroscopy air kerma in the transcarotid group (682.82 ± 713.48 mGy vs 2141 ± 2055 mGy; P < .001), although fluoroscopy dose-area product did not differ between the groups. There was no difference between the groups with respect to in-hospital or 30-day mortality (0% vs 3%; P = .355), stroke (3% vs 8%; P = .393), or vascular complication (3% vs 4%; P = .840). CONCLUSIONS: The transcarotid and the transsubclavian approaches have similar safety and efficacy outcomes. The transcarotid approach had a shorter procedure duration and a trend toward lower fluoroscopy duration and radiation exposure.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Amer MR, Mosleh W, Joshi S, et al. Comparative Outcomes of Transcarotid and Transsubclavian Transcatheter Aortic Valve Replacement. Ann Thorac Surg. 2019. PMID: 31279787. doi:10.1016/j.athoracsur.2019.05.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。